BackCRISPR Therapeutics AG Overview

CRISPR Therapeutics AG Receivables

Track CRISPR Therapeutics AG's receivables ($0) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Receivables
$0.00

Peer trimmed avg / median

Loading

CRISPR Therapeutics AG Receivables History

Loading

CRISPR Therapeutics AG vs. peers: Receivables Comparison

Loading

CRISPR Therapeutics AG Receivables Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

CRISPR Therapeutics AG (CRSP) FAQ

As of the most recent data (June 2026), CRSP shows a receivables of $0. In the prior-year period, the figure was $0. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, CRSP's receivables is now $0 (was $0). Pairing that YoY change with peer averages gives a clearer picture of whether CRISPR Therapeutics AG is outperforming or lagging.

Tracking CRSP's receivables over time shows whether CRISPR Therapeutics AG is scaling, shrinking, or reshaping that part of the business. The current reading is $0 In the prior-year period, the figure was $0. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this receivables page, Stockcircle has CRISPR Therapeutics AG's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect receivables (currently $0) with ownership activity and broader fundamentals.

CRISPR Therapeutics AG's receivables is $0; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.